Home » Stocks » Cortexyme

Cortexyme, Inc. (CRTX)

Stock Price: $45.75 USD -0.05 (-0.11%)
Updated Jul 10, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 1.35B
Revenue (ttm) n/a
Net Income (ttm) -48.48M
Shares Out 29.42M
EPS (ttm) -1.92
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 10, 2020
Last Price $45.75
Previous Close $45.80
Change ($) -0.05
Change (%) -0.11%
Day's Open 45.93
Day's Range 45.12 - 46.93
Day's Volume 163,812
52-Week Range 19.35 - 73.84

More Stats

Market Cap 1.35B
Enterprise Value 1.18B
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 29.42M
Float 13.11M
EPS (basic) -1.9
EPS (diluted) -1.92
FCF / Share -1.18
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.68M
Short Ratio 6.29
Short % of Float 9.81%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 6.37
Revenue n/a
Operating Income -50.95M
Net Income -48.48M
Free Cash Flow -33.34M
Net Cash 162.36M
Net Cash / Share 5.52
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -21.10%
ROE -34.12%
ROIC -52.30%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (6)

Buy 4
Overweight 0
Hold 1
Underweight 0
Sell 1

Analyst Consensus: Overweight

Price Target

(34.05% upside)
Current: 45.75
Target: 61.33
*Average 12-month price target from 6 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-39.17-12.12-10.37
Net Income-36.98-12.48-12.24
Shares Outstanding19.033.363.30
Earnings Per Share-1.94-3.71-3.70
Operating Cash Flow-33.28-11.70-9.83
Capital Expenditures-0.06-0.21-0.08
Free Cash Flow-33.33-11.91-9.90
Cash & Equivalents99.8671.727.39
Total Debt--7.17
Net Cash / Debt99.8671.720.22
Book Value115-32.63-20.28
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Cortexyme, Inc.
Country United States
Employees 23
CEO Casey Crawford Lynch

Stock Information

Ticker Symbol CRTX
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: CRTX


Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's disease and other degenerative disorders. Its lead drug candidate is COR388, an orally-administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III for use in patients with mild to moderate Alzheimer's disease. The company was incorporated in 2012 and is headquartered in South San Francisco, California.